For complete information about the report, please visit our website
https://www.reportscorner.com/reports/28657/Edoxaban-%E2%80%93-HOTSUKAI-VTE-STUDY-Results-at-ESC-13--Well-differentiated-and-should-carve-its-niche-in-VTE-patients-with-PE/Renal-impairment-/
On 1st Sep, at ESC, Daiichi-Sankyo presented positive results from the PhIII HOKUSAI-VTE study on Edoxaban in VTE (Venous thromboembolism) treatment. Edoxaban demonstrated non-inferiority in terms of efficacy and superiority in terms of safety compared to warfarin in the trial. The results are on the same lines as Eliquis and better than Xarelto and Pradaxa. Based on this data and subgroup analysis, we believe Edoxaban would be preferred primarily in those patients who present with a Pulmonary embolism (with or without DVT) and also those with renal impairment. We expect the market size for VTE treatment to be.....................
HOKUSAI –VTE Implications for ENGAGE-AF.........................
https://www.reportscorner.com/reports/28657/Edoxaban-%E2%80%93-HOTSUKAI-VTE-STUDY-Results-at-ESC-13--Well-differentiated-and-should-carve-its-niche-in-VTE-patients-with-PE/Renal-impairment-/
On 1st Sep, at ESC, Daiichi-Sankyo presented positive results from the PhIII HOKUSAI-VTE study on Edoxaban in VTE (Venous thromboembolism) treatment. Edoxaban demonstrated non-inferiority in terms of efficacy and superiority in terms of safety compared to warfarin in the trial. The results are on the same lines as Eliquis and better than Xarelto and Pradaxa. Based on this data and subgroup analysis, we believe Edoxaban would be preferred primarily in those patients who present with a Pulmonary embolism (with or without DVT) and also those with renal impairment. We expect the market size for VTE treatment to be.....................
HOKUSAI –VTE Implications for ENGAGE-AF.........................
No comments:
Post a Comment